N. et al. Higher dose alectinib for advancedRET+ NSCLC: results from theRET+ cohort of the Blood First Assay Screening Trial (BFAST), presented at the 2020 World Conference on Lung Cancer (28–31
Advanced Biosystems becomes Advanced Biologydoi:10.1002/adbi.202000626Kerstin BrachholdJohn Wiley & Sons, LtdAdvanced Biology
Preoperative neoadjuvant chemoradiation (nCRT) has been the standard treatment for locally advanced rectal cancer. Serum biomarkers to stratify patients with respect to prognosis and response to nCRT are needed due to the diverse response to the therapy.
In some studies sRAGE levels were higher in coronary disease cases, or in those having a higher atherosclerotic burden, than in control subjects (33, 34). In other studies concerning the same topic, exactly opposite results were obtained (35, 36, 37). Observed variations of sRAGE levels ...
(Fig.2hleft). Importantly, when stratifying for response to atezo/bev, CD8 TEMRAin responding tumours had a significantly higher Gini-index compared to non-responders (p = 0.045; Fig.2hright). In contrast, we did not detect significant differences in clonal expansion of CD8 TEMand CD8 ...
Treatment with camrelizumab plus tyrosine kinase inhibitors with or without TACE for intermediate-advanced hepatocellular carcinoma: a clinical efficacy and safety study Yaolin Yin Yaolin Yin Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China; Inst...
But the stakes with artificial intelligence aremuchhigher and not just from an existential point of view. At least with nuclear weapons, the worst case scenario plays out quickly. All the bombs go off and we all burn up in a nuclear fire. If we’re lucky, we don’t see it coming and...
The higher dose tolerated, typically the better the outcome. In the LIFE trial, these patients took a reduced dose and neither this treatment nor valsartan decreased the median NT-proBNP levels below baseline, suggesting more work needs to be done to favorably alter the trajectory ...
1 immunotherapy. The surfaces of PLGA NPs were modified by different chemical groups to bind tumor antigens; however, although all other AC-NPs except mPEG AC-NPs loaded plenty of proteins, PLGA and Mal AC-NPs showed a higher ability to improve the immunotherapeutic efficacy (Fig.4) [172]....
/PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Center for Drug Evaluation (CDE) of...